StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.03 | $1.05 | +1.94% | 0.0M |
| 05-12 | $1.04 | $1.04 | +0.00% | 0.0M |
| 05-13 | $1.04 | $1.03 | -0.96% | 0.1M |
| 05-14 | $1.03 | $1.01 | -1.94% | 0.0M |
| 05-15 | $1.02 | $1.01 | -0.98% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for IRIX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for IRIX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2026 2026-01-03 | Q3 2025 2025-09-27 | Q2 2025 2025-06-28 | Q1 2025 2025-03-29 |
|---|---|---|---|---|
Revenue | $52.67M | $37.95M | $25.47M | $11.90M |
Operating Income | $-2.57M | $-2.56M | $-1.15M | $-205.00K |
Net Income | $-4.44M | $-4.25M | $-2.68M | $-1.69M |
EPS (Diluted) | $-0.26 | $-0.25 | $-0.16 | $-0.10 |
Total Assets | $29.15M | $28.35M | $31.59M | $34.24M |
Total Liabilities | $24.23M | $23.67M | $25.53M | $27.38M |
Cash & Equivalents | $6.03M | $5.57M | $6.78M | $7.24M |
Free Cash Flow OCF − CapEx | $-2.26M | $-2.74M | $-1.57M | $-1.16M |
Shares Outstanding | 17.31M | 17.05M | 16.81M | 16.79M |
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.